• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

50.87 +1.00 (+2.01%)
Streaming Delayed Price Updated: 1:32 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear ↗
Today 9:20 EST
Moderna made a fortune with COVID vaccines, but revenue has since declined. 
Via The Motley Fool
News headline image
Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January. ↗
February 21, 2026
Laffont's new addition may represent an exciting recovery story. 
Via The Motley Fool
Topics Artificial Intelligence
Friday's session: gap up and gap down stock in the S&P500 index ↗
February 20, 2026
Via Chartmill
News headline image
Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions
February 20, 2026
Moderna’s fourth quarter results were received positively by the market, reflecting a combination of better-than-expected revenue and effective cost management. Management cited the successful U.S.... 
Via StockStory
Topics Earnings
Moderna Inc (NASDAQ:MRNA) Beats Q4 2025 Estimates Amid Post-Pandemic Transition ↗
February 13, 2026
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
February 19, 2026
Via Chartmill
News headline image
Moderna to Present at Upcoming Conferences in March 2026
February 19, 2026
Via ACCESS Newswire
News headline image
3 Once-in-a-Decade Buying Opportunities ↗
February 18, 2026
Bargain-hunters should give these stocks a close look. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Moderna (MRNA) Stock Is Trading Up Today
February 18, 2026
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.9% in the afternoon session after the U.S. Food and Drug Administration (FDA) reversed an earlier decision and agreed to review the... 
Via StockStory
Topics Economy
These S&P500 stocks are moving in today's session ↗
February 18, 2026
Via Chartmill
News headline image
Why Moderna Stock Just Popped ↗
February 18, 2026
So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy? 
Via The Motley Fool
Wednesday's session: gap up and gap down stock in the S&P500 index ↗
February 18, 2026
Via Chartmill
News headline image
Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review ↗
February 18, 2026
The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026. 
Via Stocktwits
What's going on in today's pre-market session: S&P500 movers ↗
February 18, 2026
Via Chartmill
News headline image
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
February 18, 2026
Via ACCESS Newswire
News headline image
3 Stocks Under $50 with Warning Signs
February 17, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
February 17, 2026
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
February 17, 2026
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Shopify's Whiplash Day ↗
February 17, 2026
It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call. 
Via The Motley Fool
News headline image
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
February 17, 2026
Via ACCESS Newswire
News headline image
3 Cash-Burning Stocks That Fall Short
February 15, 2026
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy
News headline image
MRNA Q4 Deep Dive: New Vaccines, Cost Controls, and Pipeline Milestones Shape Outlook
February 14, 2026
Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its non-GAAP loss of $2.11 per share was 20.2%... 
Via StockStory
News headline image
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results
February 13, 2026
Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s... 
Via MarketMinute
Topics Earnings
News headline image
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know
February 13, 2026
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
Top S&P500 movers in Friday's session ↗
February 13, 2026
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index ↗
February 13, 2026
Via Chartmill
News headline image
Moderna (MRNA) Q4 2025 Earnings Call Transcript ↗
February 13, 2026
Moderna (MRNA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Moderna (NASDAQ:MRNA) Exceeds Q4 CY2025 Expectations
February 13, 2026
Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its GAAP loss of $2.11 per share was 18.9% above... 
Via StockStory
Topics Artificial Intelligence
News headline image
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
February 13, 2026
Via ACCESS Newswire
News headline image
Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI Data: Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today ↗
February 13, 2026
Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ. 
Via Stocktwits
Topics Bonds ETFs Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap